Great interview, Brentie! I had it broken downThis is a very encouraging interview for CytoDyn and leronlimab, particularly because of how Dr. Jay Lalezari describes the science behind the CLOVER trial.
The article was published today, November 3, 2026, in Pharmaceutical Executive.
[Read the Pharmaceutical Executive interview](https://www.pharmexec.com/view/-positive-reading-leronlimab-mean-industry-thinks-repurposing-old-biologics-oncology-?utm_source=chatgpt.com)
## My five takeaways
1\. Lalezari believes leronlimab is fundamentally different.
He argues that leronlimab isn't simply an older HIV drug being repurposed for cancer. Its ability to block CCR5 may interfere with the protective tumor microenvironment that helps cancer evade the immune system.
That is a much more significant proposition than merely improving the effectiveness of chemotherapy.
2\. The CLOVER ctDNA results are central to his confidence.
Lalezari describes the early circulating tumor DNA findings as compelling evidence of biological activity.
The combination of early ctDNA reductions, dose-response observations, and tumor imaging results is encouraging. However, because CLOVER combines leronlimab with TAS-102 and bevacizumab, the contribution of leronlimab itself still needs stronger clinical confirmation. 
[image](https://www.google.com/s2/favicons?domain=https://www.pharmexec.com\&sz=32)
PharmExec+1
3\. He connects colorectal cancer and triple-negative breast cancer through one mechanism.
This may be the most important scientific implication.
Lalezari believes CCR5 blockade could alter immune signaling in different solid tumors. The breast cancer observations involving PD-L1 expression and prolonged survival provide a reason to investigate whether the mechanism extends beyond colorectal cancer.
The five-year survival observations are particularly interesting, although the small, nonrandomized patient groups limit what can be concluded. 
[image](https://www.google.com/s2/favicons?domain=https://ascopubs.org\&sz=32)
Journal of Clinical Oncology+1
4\. His confidence appears to have increased considerably.
One of the interview's strongest statements is his belief that leronlimab's success is becoming inevitable.
That is an extraordinary expression of confidence from the company's CEO and CMO.
It is meaningful as a statement of management's conviction, but it should not be confused with independent confirmation of efficacy or regulatory success.
5\. The next clinical results matter more than the interview itself.
The key question is whether the encouraging biomarkers translate into confirmed objective responses, durable disease control, progression-free survival, and eventually improved overall survival.
Those outcomes will determine how seriously potential pharmaceutical partners and regulators view leronlimab.
## What I find most significant
You and I have discussed how CCR5 may influence several mechanisms cancer uses to survive: immune-cell trafficking, immunosuppressive signaling, metastasis, and resistance to treatment.
This interview brings those ideas together in a coherent scientific hypothesis.
What makes it particularly interesting is that Lalezari isn't describing leronlimab as just another chemotherapy addition. He is describing a possible way to change the biological environment in which cancer operates.
If that mechanism is confirmed in larger, well-controlled clinical trials, leronlimab could have applications across multiple cancer types.
That would be a much larger opportunity than colorectal cancer alone.
## My assessment as an investor
I would consider this interview another positive development in CytoDyn's scientific narrative, especially when viewed alongside the October ESMO presentation and the breast cancer survival findings.
But the interview is not new independent clinical evidence. Its importance lies in the CEO's interpretation of the accumulating data.
The upcoming ASCO GI results could be a major inflection point if they establish that the early biological signals correspond to meaningful and durable clinical benefits.
One additional point: Pharmaceutical Executive interviewing Lalezari provides industry-facing exposure, but it does not establish that major pharmaceutical companies have endorsed the drug.
My bottom line: The scientific rationale is becoming more compelling, but clinical validation remains the deciding factor.
And given your interest in CytoDyn's long-term potential, I think the most important question raised by this interview is whether CCR5 blockade could become a treatment platform rather than a therapy limited to one cancer indication. 
The article was published today, November 3, 2026, in Pharmaceutical Executive.
[Read the Pharmaceutical Executive interview](https://www.pharmexec.com/view/-positive-reading-leronlimab-mean-industry-thinks-repurposing-old-biologics-oncology-?utm_source=chatgpt.com)
## My five takeaways
1\. Lalezari believes leronlimab is fundamentally different.
He argues that leronlimab isn't simply an older HIV drug being repurposed for cancer. Its ability to block CCR5 may interfere with the protective tumor microenvironment that helps cancer evade the immune system.
That is a much more significant proposition than merely improving the effectiveness of chemotherapy.
2\. The CLOVER ctDNA results are central to his confidence.
Lalezari describes the early circulating tumor DNA findings as compelling evidence of biological activity.
The combination of early ctDNA reductions, dose-response observations, and tumor imaging results is encouraging. However, because CLOVER combines leronlimab with TAS-102 and bevacizumab, the contribution of leronlimab itself still needs stronger clinical confirmation. 
[image](https://www.google.com/s2/favicons?domain=https://www.pharmexec.com\&sz=32)
PharmExec+1
3\. He connects colorectal cancer and triple-negative breast cancer through one mechanism.
This may be the most important scientific implication.
Lalezari believes CCR5 blockade could alter immune signaling in different solid tumors. The breast cancer observations involving PD-L1 expression and prolonged survival provide a reason to investigate whether the mechanism extends beyond colorectal cancer.
The five-year survival observations are particularly interesting, although the small, nonrandomized patient groups limit what can be concluded. 
[image](https://www.google.com/s2/favicons?domain=https://ascopubs.org\&sz=32)
Journal of Clinical Oncology+1
4\. His confidence appears to have increased considerably.
One of the interview's strongest statements is his belief that leronlimab's success is becoming inevitable.
That is an extraordinary expression of confidence from the company's CEO and CMO.
It is meaningful as a statement of management's conviction, but it should not be confused with independent confirmation of efficacy or regulatory success.
5\. The next clinical results matter more than the interview itself.
The key question is whether the encouraging biomarkers translate into confirmed objective responses, durable disease control, progression-free survival, and eventually improved overall survival.
Those outcomes will determine how seriously potential pharmaceutical partners and regulators view leronlimab.
## What I find most significant
You and I have discussed how CCR5 may influence several mechanisms cancer uses to survive: immune-cell trafficking, immunosuppressive signaling, metastasis, and resistance to treatment.
This interview brings those ideas together in a coherent scientific hypothesis.
What makes it particularly interesting is that Lalezari isn't describing leronlimab as just another chemotherapy addition. He is describing a possible way to change the biological environment in which cancer operates.
If that mechanism is confirmed in larger, well-controlled clinical trials, leronlimab could have applications across multiple cancer types.
That would be a much larger opportunity than colorectal cancer alone.
## My assessment as an investor
I would consider this interview another positive development in CytoDyn's scientific narrative, especially when viewed alongside the October ESMO presentation and the breast cancer survival findings.
But the interview is not new independent clinical evidence. Its importance lies in the CEO's interpretation of the accumulating data.
The upcoming ASCO GI results could be a major inflection point if they establish that the early biological signals correspond to meaningful and durable clinical benefits.
One additional point: Pharmaceutical Executive interviewing Lalezari provides industry-facing exposure, but it does not establish that major pharmaceutical companies have endorsed the drug.
My bottom line: The scientific rationale is becoming more compelling, but clinical validation remains the deciding factor.
And given your interest in CytoDyn's long-term potential, I think the most important question raised by this interview is whether CCR5 blockade could become a treatment platform rather than a therapy limited to one cancer indication. 
5
